Table 2.

Criteria for preliminary ranking of topics

Criteria related to health burden	What is the potential public health impact based on the prevalence/incidence of the disorder, the prevalence of gene variants, or the number of individuals likely to be tested?
	What is the severity of the disease?
	How strong is the reported relationship between a test result and a disease/drug response?
	Is there an effective intervention for those with a positive test or their family members?
	Who will use the information in clinical practice (e.g., healthcare providers, payers) and how relevant might this review be to their decision-making?
Criteria related to practice issues	What is the availability of the test in clinical practice?
	Is an inappropriate test use possible or likely?
	What is the potential impact of an evidence review or recommendations on clinical practice? On consumers?
Other considerations	How does the test add to the portfolio of EGAPP evidence based reviews? As a pilot project, EGAPP aims to develop a portfolio of evidence reviews that adequately tests the process and methodologies.
	Will it be possible to make a recommendation, given the body of data available? EGAPP is attempting to balance selection of somewhat established tests versus emerging tests for which insufficient evidence or unpublished data are more likely.
	Are there other practical considerations? For example, avoiding duplication of evidence reviews already underway by other groups.
	How does this test contribute to diversity in reviews? In what category is this test? As a pilot project, EGAPP aims to consider different categories of tests (e.g., pharmacogenomics or cancer), mutation types (e.g., inherited or somatic) or test types (e.g., predictive or diagnostic).